Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine. 10 stocks we like ...
Regencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM. It lists indications such as neurocognitive disorders and infectious diseases as areas of ...
Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value ...
Regencell Bioscience Holdings (RGC) remains pre-revenue, with no evidence of customer demand or clinically validated progress from external sources. RGC's liquidity is precarious, with cash on hand ...
Regencell Bioscience is downgraded from 'buy' to 'hold.' Key risks include a $500M ATM equity program, a DOJ investigation overhang, and a breach of $10 in technical support. RGC's valuation remains ...
LOS ANGELES, May 12, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: ...
Regencell Bioscience Holdings RGC-2.19%decrease; down pointing triangle, a small Hong Kong company, is grappling with a struggling business and a Justice Department investigation. Yet for reasons that ...
IF YOU SUFFERED A LOSS ON YOUR REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can ...
Regencell specializes in developing traditional Chinese medicine products, particularly in neuroscience and infectious diseases. The company's targets include ADHD, autism, and COVID-19. Investors ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results